Double Modulation of 5-Fluorouracil by Trimetrexate and Leucovorin in Patients with Advanced Colorectal Carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 2, 2004, Pages 149-154

  Machiavelli, Mario R ^a,b   Salum, G ^a   Perez J E ^a   Ortiz, E H ^a   Romero, A O ^a   Bologna, F ^a   Vallejo, C T ^a   Lacava, J A ^a   Dominguez, M E ^a   Leone, B A ^a  

^a Grp Oncol Coop del Sur (GOCS)   (Argentina)

^b GOCS Neuquén ^*  (Argentina)

Author keywords

5 FU; Biomodulation; Colorectal cancer; Leukovorin; Trimetrexate

Indexed keywords

FLUOROURACIL; FOLINIC ACID; TRIMETREXATE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; TREATMENT FAILURE; TUMOR LOCALIZATION; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT FAILURE; TRIMETREXATE;

EID: 11144356381     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000054903.27866.31     Document Type: Article

References (45)

1. Allegra CJ. Biochemical modulation: a modality that has come of therapeutic age. J Clin Oncol 1991;9:1723-6.
2. Leyland-Jones B, O'Dwyer PJ. Biochemical modulation: application of laboratory models to the clinic. Cancer Treat Rep 1966;70:219-28.
3. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12960-9.
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
5. Lin JT, Bertino JR. Update on trimetrexate, a folate antagonist with antineoplastic and anti-protozoal properties. Cancer Invest 1994;9:159-72.
6. Bertino JR, Sawicki WL, Moroson BA, et al. 2,4-diamino-5methyl-6[(3,4,5-trimethoxyanilino)methyl]quinazoline(tmq), a potent non-classical folate antagonist inhibitor-1. Effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol 1979;28:1983-7.
7. Kamen BA, Eibl B, Cashmore A, et al. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5methyl-6[(3,4,5-trimethoxyanilino)methyl]quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 1984;331697-9.
8. Rodenhuis S, McGuire JJ, Sawicki WI, et al. Effects of methotrexate and of the 'non-classical' folate antagonist trimetrexate on human leukemia cells. Leukemia 1987;1:116-20.
9. Leopold WR, Dykes DJ, Griswold DP Jr. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia. NCI Monogr 1987;5:99-104.
10. Elliot WL, Howard CT, Dykes DJ, et al. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res 1989;49:5586-90.
11. Sobrero A, Romanini A, Russello O, et al. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 1989;25:977-82.
12. Lin JT, Cashmore AR, Baker MA, et al. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res 1987;47:609-16.
13. Grochow LB, Noe DA, Ettinger DS, et al. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol 1989;24:314-20.
14. Grochow LB, Noe DE, Dole GB, et al. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 1989;81:124-30.
15. Brown T, Fleming T, McDonald J. A randomized trial of two schedules of trimetrexate (TMTX) versus 5-fluorouracil (5-FU) in colorectal carcinoma: a Southwest Oncology Group Study [Abstract 419A]. Proc Am Soc Clin Oncol 1988;7:109.
16. Conti JA, Kemeny NE, Tong W, et al. Final results of a phase I trial of sequential trimetrexate (TMTX), fluorouracil (FU) and high-dose leucovorin (LV) in previously treated patients (PTS) with gastrointestinal (GI) carcinoma (CA). Proc Am Soc Clin Oncol 1997;16:A1014.
17. Kaplan E, Gerish R, Lindemann K, et al. Community experience with trimetrexate, 5-FU, and leucovorin (TLF) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:A1040.
18. Blanke CD, Kasimis B, Schein P, et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997;15:915-20.
19. Kreuser DE, Szelenyi H, Hohemberger P, et al. Trimetrexate, 5-fluorouracil and folinic acid: an effective regimen in previously untreated patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1997;16:A1047.
20. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazards function for interpreting survival data: an investigator's primer. J Clin Oncol 1985;3:1418-31.
23. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
24. Sobrero A, Kerr D, Glimelius B, et al. New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 2000;36:559-566.
25. Sheithauer W, Rosen H, Kornek GW, et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-5.
26. Allen Mersh TG, Earlam S, Fordy C. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60.
27. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. A randomized trial. J Clin Oncol 1992;10:904-11.
28. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
29. Rougier P, Van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
30. Leone BA, Romero A, Rabinovich MG, et al. Double modulation of 5-fluorouracil by methotrexate and leucovorin in advanced colorectal carcinoma. Int J Oncol 1993;3:995-9.
31. Machover D, Grison X, Goldschmidt E, et al. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. J Natl Cancer Inst 1992;84:321-7.
32. Peters GJ, Hoekman K, Van Groeningen CJ, et al. High dose leucovorin (HD-LV), but not low dose LV (LD-LV) potentiates 5-fluorouracil (5FU) induced inhibition of thymidylate synthetase (TS) in human colon tumors. Proc Am Soc Clin Oncol 1993;12:135.
33. Romero AO, Pérez JE, Lacava JA, et al. Double modulation of 5-fluorouracil by methotrexate and high-dose I-leucovorin in advanced colorectal cancer. Am J Clin Oncol 1998;21:94-8.
34. Stewart JA, McCormack JJ, Tong W, et al. Phase I clinical and pharmacokinetic study of trimetrexate using a daily X 5 schedule. Cancer Res 1988;48:5029-35.
35. Bishop JF, Raghavan D, Olver IN, et al. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 1989;24:246-50.
36. Jolivet J, Landry L, Pinard MF, et al. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987;20:169-72.
37. Reece PA, Morris RG, Bishop JF, et al. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. Cancer Res 1987;47:2996-9.
38. Fanucchi MP, Walsh TD, Fleisher M, et al. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 1987;47:3303-8.
39. Allegra CJ, Jenkins J, Weiss RB, et al. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule. Invest New Drugs 1990;8:159-66.
40. Huan SD, Legha SS, Raber MN, et al. Phase I studies of trimetrexate using single and weekly dose schedules. Invest New Drugs 1991;9:199-206.
41. Brown TD, Fleming TR, Goodman PJ, et al. A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer. A Southwest Oncology Group study. Anticancer Drugs 1995;6:219-23.
42. Maroun J, Leiby J, Capizzi R, et al. Efficacy of trimetrexate (CI-898, TMTX) in patients with solid tumors [Abstract]. Clin Res 1987;35:529A.
43. Ajani J, Abbruzzese J, Faintuch J, et al. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest 1990;8:619-21.
44. Punt CJ, Keizer HJ, Douma J, et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomized European Study. Ann Oncol 2002;13:81-6.
45. Blanke CD, Shultz J, Cox J, et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 2002;13:87-91.